BioCentury
ARTICLE | Company News

Repligen, Pfizer deal

September 9, 2013 7:00 AM UTC

Repligen received a $1 million milestone payment from Pfizer under a 2012 deal granting the pharma exclusive, worldwide rights to develop and commercialize Repligen's spinal muscular atrophy (SMA) program. The milestone, which is the first under the deal, was triggered by Repligen completing technology transition obligations and completing the first two cohorts in a Phase I trial evaluating RG3039 in healthy volunteers. ...